An international team of researchers has discovered a new range of arsenic broad-spectrum antibiotics that they want fight against the emergence of antibiotic-resistant bacteria, a problem that is already causing millions of deaths and that this could cause a health emergency in the future, according to the World Health Organization (WHO).
Barry P. Rosen, from the Medical School of Herbert Wertheim, International University of Florida (FIU), suggested that the new antibiotic, called Arzinotrincin (AST) is a "natural product produced by soil bacteria".
[¿Qué son los “fagos” y por qué podrían salvar a la humanidad de una catástrofe?][Los problemas que enfrentan los antibióticos en la actualidad]
Rossen, co-author of the study published in Nature's Communication Biology, said AST is "the first and only known natural antibiotic" that contains arsenic.
The study suggests that, although it contains this substance, researchers say that AST toxicity in human blood cells "It does not kill human cells in tissue culture."
"People are afraid when they hear the word arsenic, because it can be toxin and carcinogen, but the use of arsenic as antimicrobial and anticancer agents is well establishedRosen said.
According to US Centers for Disease Control and Prevention (CDC), some Two million people are infected every year in the country with drug-resistant bacteria, of which 23,000 are dying.
The World Health Organization (WHO) has warned that "an increasing number of infections, such as pneumonia, tuberculosis, gonorrhea and salmonella, are becoming more difficult to treat because Antibiotics used for treatment are less effective"
"We have run out of tools to combat these diseases. We need a powerful new antibiotic to address this problem ", said Japan's Masafumi Yoshinaga, co-author of the report.
Scientists have discovered thisThe new antibiotic is "very effective" against some of the bacteria that have the greatest impact on public health, such as E.coli, which can cause diarrhea, gastroenteritis and other digestive disorders.
He also worked against Mycobacterium bovis, which causes tuberculosis in cattle, which is predicted to be used to treat this human disease, although they promote it new tests will be needed.
The team hopes to work with the pharmaceutical industry to develop the drug compound, a process that can last for ten years, although Rosen recalled that more than 90% of potential drugs "fail in clinical trials".
The study was conducted by researchers from the Department of Cell Biology and Pharmacology of the Institute for Agro-Environmental Sciences (NARO), Japan.
Follow us on Twitter …